NB-4746 by Nura Bio for Amyotrophic Lateral Sclerosis: Likelihood of Approval

NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis.

Procept wins FDA clearance for updated prostate surgery robot

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Procept Biorobotics has received 510(k)

August 22, 2024

AliveCor and Clario Partner to Offer Decentralized Clinical Trials- Focused Six-Lead ECG Solutions

What You Should Know: Clario announced an expansion to its collaboration with AliveCor to enable trial participants to collect medical-grade six-lead ECG readings in the

August 16, 2023

Obesity drugmaker lands first biopharma uplisting onto Nasdaq since last summer

For the first time since last summer, a biotech has uplisted from an over-the-counter stock exchange to the Nasdaq. Such a move has become a

April 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.